Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Sponsor
Memorial Sloan Kettering Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT02677064
Collaborator
(none)
301
3
84
100.3
1.2

Study Details

Study Description

Brief Summary

The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.

Condition or Disease Intervention/Treatment Phase
  • Other: assessments

Study Design

Study Type:
Observational
Anticipated Enrollment :
301 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia, Myelodysplastic Syndrome and Myelproliferative Neoplasms
Study Start Date :
Feb 1, 2016
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
patients with acute leukemia (AML or ALL)

Other: assessments
Thus, a prospective observational study in which all newly diagnosed or newly relapsed acute leukemia patients would be registered close to the beginning of induction or re-induction therapy would allow us to follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.

Outcome Measures

Primary Outcome Measures

  1. number of patients who proceed to transplant [3 years]

    determine whether an individual patient proceeded to HCT when he or she was considered eligible (based on NCCN guidelines.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with newly diagnosed or relapsed acute leukemia. Patients undergoing reinduction due to primary induction failure are also eligible.

  • 18 years of age or older and 75 years of age or younger, admitted for treatment on the Adult Leukemia Service.

Exclusion Criteria:
  • Patients with relapsed acute leukemia post-allogeneic transplant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hartford Healthcare Cancer Institute @ Hartford Hospital Hartford Connecticut United States 06102
2 Memorial Sloan Kettering Cancer Center New York New York United States 10065
3 Lehigh Valley Health Network Allentown Pennsylvania United States 18103

Sponsors and Collaborators

  • Memorial Sloan Kettering Cancer Center

Investigators

  • Principal Investigator: Boglarka Gyurkocza, MD, Memorial Sloan Kettering Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT02677064
Other Study ID Numbers:
  • 16-024
First Posted:
Feb 9, 2016
Last Update Posted:
Aug 19, 2022
Last Verified:
Aug 1, 2022
Keywords provided by Memorial Sloan Kettering Cancer Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 19, 2022